Why the study?
Do new anticoagulants (fondaparinux, idraparinux, ximelagatran) prevent and treat venous thromboembolism as effectively and safely as conventional anticoagulants in high-risk patients?
Do new anticoagulants (fondaparinux, idraparinux, ximelagatran) prevent and treat venous thromboembolism as effectively and safely as conventional anticoagulants in high-risk patients?
New target-specific anticoagulants demonstrate comparable efficacy and safety to traditional therapies for VTE, with significant practical advantages including predictable pharmacokinetics and no routine monitoring requirement.
Anticoagulant therapy is effective at preventing the development of venous thromboembolism in high-risk patients, and reduces morbidity and mortality in individuals with established thromboembolic disease. Vitamin K antagonists and heparins are currently the most commonly used anticoagulant drugs, but they have practical limitations. Therefore, new antithrombotic agents with predictable dose-responses (thereby decreasing the need for monitoring without compromising efficacy or safety), ideally available in an oral formulation and with a rapidly reversible anticoagulant effect, are needed. New drugs fulfilling some of the above criteria have been developed and have proven to be effective agents for the treatment and prevention of venous thromboembolism.
No takes yet. Share an insight, caveat, or question.
McRae et al. (2005) conducted a review in Venous thromboembolism (n=7,344). Fondaparinux vs. Enoxaparin was evaluated on Incidence of venous thromboembolism (VTE) (OR reduction 55.2%, 95% CI 45.8-63.1, p=<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More on Anticoagulation in AFMore from Vascular Health and Risk Management